Tagged with Biotech,

Global Andrea Johnston,* Senior Phorum Director at BioPhorum,** argues that the biopharma industry’s rapid embrace of digital twins is being undermined by a fundamental problem: agreeing what a digital twin actually is. Drawing on fresh benchmarking data from leading manufacturers, Johnston contends that this lack of shared definition is slowing regulatory…

USA Chris Peetz, co-founder and CEO of Mirum Pharmaceuticals, reflects on the company’s journey from rescuing overlooked rare disease programs to building a growing global pharmaceutical company. He discusses Mirum’s expanding commercial portfolio, pipeline momentum, and disciplined acquisition strategy, while emphasizing the importance of patient-centered execution in rare disease. Peetz also…

China Cancer drug development has produced an abundance of therapies, yet outcomes in solid tumours remain constrained by resistance and relapse. In this interview, Zaiqi Wang, Chairman and CEO of InxMed, explains why the company starts from tumour defence biology rather than individual targets, and how this perspective informs its combination…

China Shaped by decades across US biotech, big pharma, and China’s high-intensity innovation environment, Dr Jing Li brings a rare end-to-end perspective on how biologics move from idea to impact. In this interview, he explains why VelaVigo is built around first-in-class biology, disciplined execution, and global partnering, and how those choices…

China EnCureGen’s founder Dr Aimin Hui draws on a career spanning oncology, molecular biology and global R&D leadership to pursue the next generation of mRNA therapeutics. His role in driving the Fosun-BioNTech COVID-19 collaboration shaped his belief that mRNA can extend far beyond infectious disease, and from Guangzhou International Bio Island…

Taiwan Professor Chi-Huey Wong serves as President of the Institute for Biotechnology and Medicine Industry (IBMI) in Taiwan, bringing decades of distinguished experience from top-tier US research institutions including MIT, Scripps Research and his tenure as President of Academia Sinica. With a unique vantage point spanning both American and Taiwanese scientific…

Taiwan Built around an engineering mindset and a clear view of where a smaller biotech can compete, Pharmosa is pursuing a differentiated path in pulmonary hypertension and related rare diseases through drug-device combination therapies. In this discussion, Pei Kan outlines how scientific focus, selective partnerships, disciplined capital allocation, and early investment…

USA Glenn Robertelli, CEO of RI Bio, is shaping Rhode Island into a rising life sciences hub through strategic partnerships, innovative programs, and support for early-stage biotech. Despite the state’s small size, Rhode Island ranks fourth nationally in NIH funding and is a top ten leader in bioscience patents and medical…

Taiwan With over two decades of global pharmaceutical experience at Eli Lilly and Allergan, Dr Jimmy Chang returned to Taiwan to lead TaiMed Biologics, Taiwan’s first biotech to successfully commercialise a biologic therapy worldwide. Now CEO, Chang has overseen the company’s evolution from a single-asset HIV specialist to a globally recognised…

Taiwan Taiwanese biotech Caliway is trying to redefine fat reduction as measurable medicine. Founded in 2012, Caliway has advanced its first-in-class candidate CBL-514 into pivotal Phase III development in the US, following ten completed clinical studies. President Antony Hsu outlines the science behind selective adipocyte apoptosis, the regulatory strategy behind the…

Taiwan Frederic Kuo, founder and CEO of Fethiann, established the company in 2017 within Taiwan’s Hsinchu Science Park. With a PhD background and extensive experience in new drug development, Frederick has positioned Fethiann as Taiwan’s sole specialist in natural phytochemical active pharmaceuticals. The company’s unique business model integrates Active Phytochemicals Ingredient…

USA Neil F. McFarlane, President and CEO of Zevra Therapeutics, reflects on how his experiences in clinical practice, military service, and leadership roles across biotech and mid-sized pharma come together and led him to this moment. Under McFarlane, Zevra is driven by the urgency of patient needs and engaging with patient…